The design of the study is what gives it its power. Rather than comparing a single patient group with controls, the team recruited 111 adolescents spanning a gradient of risk: 25 with a diagnosis of bipolar I disorder who were currently euthymic, meaning their mood was stable at the time of testing; 32 classified as high-risk, typically because of a family history of the illness; 24 deemed ultra-high risk, showing attenuated or subclinical manic symptoms identified through instruments such as the Bipolar Prodrome Symptom Scale-Prospective; and 30 healthy controls. This four-tier structure allowed the investigators to ask whether neurocognitive alterations deepen as one moves along the continuum from familial risk toward full-threshold illness — a question that cross-sectional comparisons of patients and controls alone cannot answer.

Each participant completed a battery of behavioral tasks and questionnaires targeting four cognitive-affective domains. Risk-taking was probed with the Modified Balloon Analog Risk Task, in which participants inflate virtual balloons for points while weighing the danger of an explosion, and with the Iowa Gambling Task, a classic decision-making paradigm that requires learning, often without conscious awareness, which of several card decks yields long-term gains. Impulsivity was measured behaviorally with a Go/No-Go Task, which tests the ability to suppress a prepotent motor response, and subjectively with the Barratt Impulsivity Scale-11, a widely used self-report instrument that decomposes impulsivity into attentional, motor, and non-planning facets. Reward sensitivity was assessed with the Behavioral Inhibition/Behavioral Activation Scale, which quantifies the strength of approach and avoidance motivational systems. Finally, emotional conflict resolution was tested with an Emotional Stroop Task, in which participants must name the color of words while ignoring their emotional content, forcing the brain to resolve interference between affective salience and task demands.

The statistical approach was deliberately conservative. Group comparisons used the Kruskal-Wallis test, appropriate for non-normally distributed data, with Benjamini-Hochberg false discovery rate correction to control for multiple comparisons, and the most robust findings were further checked against the stricter Bonferroni threshold. Multinomial logistic regression, adjusted for age and sex, then tested which measures best classified adolescents into the four groups, and receiver operating characteristic analysis quantified diagnostic discrimination. This layered pipeline matters because the field of psychiatric biomarkers is littered with findings that evaporate under multiple-comparison scrutiny; here, the authors explicitly flagged which results survived which level of correction.

The standout result was accuracy on the Emotional Stroop Task. Conflict accuracy — the ability to correctly respond despite emotional interference — was the most consistent discriminator in the entire study. It separated the high-risk, ultra-high-risk, and bipolar groups from healthy controls, and, crucially, it also distinguished the bipolar group from both risk groups. In other words, deficits in resolving emotional conflict appear not merely as a consequence of the illness but as a feature that intensifies across the risk continuum, making it one of the most promising candidate markers identified. The regression analysis underscored this: emotional conflict accuracy discriminated the combined ultra-high-risk and bipolar groups from the combined healthy and high-risk groups with an area under the curve of 0.923, a level of discrimination that, if replicated, would be remarkable for a single behavioral measure in psychiatry. The authors are careful to note, however, that this cut-off is exploratory and derived from a modest sample.

Decision-making under risk also told a coherent story. Lower net scores on the Iowa Gambling Task differentiated all three clinical groups — bipolar, high-risk, and ultra-high-risk — from healthy controls, suggesting that impaired affective decision-making is a broad vulnerability feature present even before illness onset. On the Modified Balloon Analog Risk Task, a higher average number of pumps — a direct behavioral index of risk-taking — differentiated the ultra-high-risk and bipolar groups from controls in the adjusted models. Notably, this elevated risk-taking in the ultra-high-risk group correlated with concurrent subclinical manic symptoms, hinting that the balloon-pumping behavior may capture something phenomenologically close to the emerging hypomanic temperament. Group differences on the Emotional Stroop, Iowa Gambling Task, Barratt Impulsivity Scale, and Go/No-Go task survived both false discovery rate and Bonferroni correction, whereas the balloon task differences survived false discovery rate correction only.

Perhaps the most clinically useful aspect of the findings is the differential pattern across impulsivity subdomains. Non-planning impulsivity, reward sensitivity, and emotional conflict resolution deficits distinguished all three clinical groups from healthy controls, positioning them as potential trait markers of vulnerability that are present from the earliest identifiable risk stage. By contrast, motor and attentional impulsivity, fun-seeking, and response inhibition deficits were more specific to the ultra-high-risk and bipolar groups, appearing only as adolescents move closer to or into full-threshold illness. This dissociation suggests a staged model of neurocognitive deterioration: a baseline vulnerability layer shared across the risk spectrum, overlaid by a later-emerging layer of inhibitory and attentional dyscontrol that may signal imminent transition. If longitudinal studies confirm this architecture, clinicians could in principle use the profile of deficits — not just their presence — to estimate where along the risk pathway a given adolescent sits.

The theoretical implications reach into long-standing models of bipolar disorder. Heightened reward sensitivity and approach motivation have been central to psychological theories of mania, and the present findings align with the idea that a hyperactive behavioral activation system, combined with impaired top-down regulation of emotional interference, creates a cognitive environment in which mood dysregulation can escalate. The anterior cingulate cortex, a region heavily implicated in conflict monitoring and error processing, is a plausible neural substrate for the Emotional Stroop deficits observed, and its dysfunction could plausibly link the affective and cognitive disturbances that characterize the bipolar prodrome. The authors themselves frame these alterations as candidate markers rather than established ones, a distinction that reflects both the strength and the limits of the evidence.

Those limits deserve emphasis. The study is cross-sectional, meaning it captures a snapshot rather than a trajectory; it cannot prove that the observed deficits predict who will convert from risk to illness, only that they covary with risk stage at a single point in time. The sample, while thoughtfully stratified, is modest — 111 adolescents across four groups — and the ultra-high-risk subgroup in particular is small. The authors also note that the striking area under the curve of 0.923 for emotional conflict accuracy should be treated as a hypothesis-generating estimate, since classification metrics derived from the same dataset used for discovery are prone to optimism. Longitudinal follow-up of high-risk and ultra-high-risk cohorts, ideally with neuroimaging and repeated cognitive assessment, will be needed to determine whether these candidate markers genuinely forecast onset and whether early intervention targeting emotional regulation could alter the course of the illness.

Even with those caveats, the study represents a meaningful step toward a long-sought goal in child and adolescent psychiatry: identifying measurable, task-based signals that stratify bipolar risk before the first full manic episode. Bipolar disorder in young people is frequently misdiagnosed, often as unipolar depression or attention deficit hyperactivity disorder, and treatment delays carry substantial costs in academic, social, and neurobiological terms. A validated cognitive profile — impaired emotional conflict resolution, compromised affective decision-making, and stage-specific impulsivity changes — could eventually complement clinical interviews and family history to sharpen risk assessment. For now, the message from Ankara and Izmir is one of cautious optimism: the cognitive fingerprints of bipolar vulnerability appear to be detectable in adolescence, arranged along a gradient that mirrors the illness itself, and waiting to be tested against the passage of time.

Subject of Research: Neurocognitive vulnerability markers across bipolar disorder risk stages in adolescents

Article Title: Neurocognitive candidate markers across bipolar disorder risk stages in adolescents

Article References: Akpınar, S., Kafali, H. Y., Kabasakal, İ., Kaya, H., Akman, A. Ö., Bora, E., & Dinç, G. Ş. (2026). Neurocognitive candidate markers across bipolar disorder risk stages in adolescents. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08732-4

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08732-4

Keywords: bipolar disorder, adolescents, ultra-high risk, emotional conflict, reward sensitivity, impulsivity, risk-taking, Iowa Gambling Task, Emotional Stroop Task, neuropsychology, prodrome, predictive markers

The research team, led by Chenyi Chen and Yawei Cheng of National Yang Ming Chiao Tung University and collaborating institutions in Taiwan, recruited 40 female breast cancer survivors, 27 of whom had been treated with chemotherapy, along with 30 age-matched healthy controls. Chemotherapy regimens consisted primarily of the standard AC combination of doxorubicin and cyclophosphamide or the FEC protocol built around 5-fluorouracil, epirubicin, and cyclophosphamide, with some patients receiving additional agents such as docetaxel. All participants were right-handed Taiwanese women aged 35 to 75 with normal or corrected-to-normal vision, and anyone with a history of neurological or psychiatric disorders was excluded. Diagnoses were clinically confirmed by physicians, and the protocol was approved by the hospital’s institutional review board.

The centerpiece of the study was a face-word emotional Stroop task performed inside an fMRI scanner. On each trial, participants saw a photograph of a face displaying either a happy or fearful expression, with an emotional word superimposed in bold red font. Sometimes the face and word matched; sometimes they clashed. Participants had to identify the facial expression while ignoring the word, a deceptively simple instruction that forces the brain to manage two competing emotional signals at once. The task is a well-validated probe of emotional attention, the preferential allocation of mental resources to emotionally salient stimuli, and of emotional conflict regulation, the ability to resolve interference between incongruent affective cues. No prior study, the authors note, had used task-based fMRI with an affective paradigm specifically designed to examine these processes in breast cancer survivors.

The behavioral and questionnaire results already hinted at something strange. On standardized measures, the non-chemotherapy survivors reported the highest affective symptom load, scoring significantly higher on combined Beck Anxiety Inventory and Beck Depression Inventory-II indices than both the chemotherapy-treated group and the healthy controls. Yet on the Stroop task, the chemotherapy-treated survivors performed worse than controls overall, and the deficit was driven almost entirely by fearful faces: their accuracy on those trials dropped to about 87 percent, compared with nearly 96 percent in controls, while accuracy on happy faces did not differ between groups. In other words, the group reporting the least emotional distress was also the group least accurate at detecting fear, a dissociation that would be invisible to any screening program relying on self-report alone.

The brain imaging sharpened the picture. In the dorsomedial prefrontal cortex, a region that integrates cognitive control with emotion regulation, chemotherapy-treated survivors showed significantly reduced activation compared with both other groups, a result that survived false-discovery-rate correction. This region is a known target of chemotherapy-related neurotoxicity, and its hypoactivation aligns with earlier work linking the drugs to prefrontal alterations. Meanwhile, the non-chemotherapy survivors displayed the opposite configuration: heightened incongruency-related interference in the parahippocampal gyrus, which supports emotionally salient memory and contextual associations, and in the insula, a hub of interoceptive awareness and salience detection that is implicated in anxiety and mood disorders. Their salience networks appeared to be working overtime, amplifying the emotional weight of conflicting cues.

Perhaps the most intriguing finding concerned the dorsal anterior cingulate cortex, a node of the brain’s conflict-monitoring machinery. In healthy controls, greater dACC activation correlated with lower affective symptom scores, a normative inverse coupling consistent with the region’s regulatory role: the better the monitoring system works, the less distress accumulates. That coupling was absent in both survivor groups, suggesting that diagnosis or treatment decouples dACC function from emotional outcomes. In the chemotherapy group, the largest fearful-versus-happy dACC difference coincided with their worst behavioral accuracy, leading the authors to speculate, cautiously, about inefficient overinvestment of cognitive resources rather than effective regulation. They stress that no electrophysiological data were collected, so this remains a hypothesis for future combined fMRI-EEG work rather than a conclusion.

Putting these threads together, the researchers propose what they call an emotional attention disruption framework. Chemotherapy, they suggest, may alter the salience network nodes that detect, prioritize, and respond to emotionally significant stimuli, including the insula, parahippocampal cortex, anterior cingulate, and dorsomedial prefrontal cortex. The behavioral consequence would be reduced interference from negative distractors; the subjective consequence would be lower scores on standard distress questionnaires. The authors are careful to label emotional blunting an interpretive hypothesis rather than a directly measured variable. They did not collect trial-by-trial valence or arousal ratings, nor instruments for alexithymia, anhedonia, or emotional avoidance, and alternative explanations such as reduced task engagement, altered semantic-visual conflict resolution, or general cognitive inefficiency cannot be excluded. Low distress in an individual survivor may still reflect authentic adaptation.

The clinical implications, if the hypothesis holds, are substantial. Current distress screening in survivorship relies almost exclusively on self-report instruments such as the Beck inventories or the Distress Thermometer. A team using those tools alone would prioritize non-chemotherapy survivors for psychosocial support and deprioritize the chemotherapy-exposed, precisely the triage the neural data call into question. The authors frame their recommendations explicitly as hypotheses for intervention trials, not evidence-based guidelines. For chemotherapy-exposed survivors, approaches that re-engage emotional attention, such as emotion-focused therapy, exposure-based methods, or affect-labeling training, might restore adaptive salience detection. For non-chemotherapy survivors showing hyper-reactive salience processing, mindfulness-based stress reduction, cognitive-behavioral therapy, or attention-bias modification might better dampen reactivity. A single standardized protocol for all survivors, they argue, is likely suboptimal.

The study’s limitations are candidly acknowledged and considerable. The cross-sectional design precludes causal inference, and the non-chemotherapy subgroup contained only 13 participants, small enough that effect-size estimates are unstable and confidence intervals wide; the authors deliberately refrained from formal mediation analysis for that reason. Several key interactions did not survive false-discovery-rate correction and are presented as descriptive. Survivors were recruited from a single hospital clinic, raising selection-bias concerns, and the emotional Stroop paradigm itself rests on the contested assumption that standardized facial configurations map onto discrete emotion categories, an assumption challenged by cross-cultural research. Near-ceiling accuracy across groups made the behavioral findings conservative, and regression to the mean cannot be ruled out without pretreatment baselines. Fatigue, sleep, hormonal change, and inflammation, all plausible modulators, were not examined.

Even with those caveats, the study marks a conceptual shift in how survivorship care might be conceived. It positions divergent emotional outcomes along a single continuum of emotional attention: hyper-reactivity, as seen in the non-chemotherapy survivors, increases vulnerability to anxiety and depression, while hypo-reactivity, as seen after chemotherapy, lowers subjective distress at the cost of reduced neural and behavioral sensitivity to affective information. Both deviate from the balanced reactivity of healthy brains. The authors suggest that behavioral proxies of emotional attention, such as emotional Stroop performance, could eventually serve as feasible adjuncts to distress screening, helping stratify survivors for mechanism-matched support without requiring scanner time. Whether either intervention strategy actually improves outcomes in the corresponding phenotype is untested and awaits randomized trials. But the core message is already clear: in cancer survivorship, silence on a questionnaire is not always the sound of health, and the brain’s quietest survivors may be the ones most in need of a closer look.

Subject of Research: Affective neural phenotypes and emotional attention in chemotherapy-treated breast cancer survivors

Article Title: Distinct affective neural phenotypes in breast cancer survivors: implications for personalized supportive care after chemotherapy

Article References: Chen, C., Chiang, H.-J., Chen, Y.-C., Fan, Y.-T., Liao, T.-T., Chen, C.-Y., & Cheng, Y. (2026). Distinct affective neural phenotypes in breast cancer survivors: implications for personalized supportive care after chemotherapy. Supportive Care in Cancer, 34(10), Article 1048. https://doi.org/10.1007/s00520-026-11271-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11271-z

Keywords: breast cancer survivorship, chemotherapy, emotional blunting, fMRI, emotional Stroop task, distress screening, salience network, dorsomedial prefrontal cortex, insula, anterior cingulate cortex, supportive care, emotion regulation